SCHEMBL20605349

SCHEMBL20605349

CCOC(=O)C1NCCc2c1c1ccccc1n2Cc1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 15/20 0.44
▸ HDAC1 Q13547 9/20 0.44
▸ HDAC2 Q92769 4/20 0.39
▸ HDAC8 Q9BY41 4/20 0.39
▸ SIRT2 Q8IXJ6 1/20 0.39
▸ SIRT1 Q96EB6 1/20 0.39
▸ HDAC3 O15379 2/20 0.39
▸ HDAC10 Q969S8 2/20 0.39
▸ NCOR2 Q9Y618 1/20 0.38
▸ F2RL3 Q96RI0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20628955 0.88 HDAC6 (0.47) HDAC6HDAC1HDAC2HDAC8HDAC3
Hydrochloric Acid SCHEMBL20605300 0.87 HDAC6 (0.46) HDAC6HDAC1HDAC2HDAC8HDAC3
SCHEMBL20628946 0.87 HDAC6 (0.41) HDAC6HDAC1HDAC2HDAC8HDAC3
SCHEMBL20635876 0.85 MEN1 (0.36) —
SCHEMBL20629339 0.81 HDAC2 (0.49) HDAC6HDAC1HDAC2HDAC8HDAC3
SCHEMBL20635518 0.76 HDAC6 (0.47) HDAC6HDAC1HDAC2HDAC8SIRT2
Hydrochloric Acid SCHEMBL20610207 0.74 HDAC6 (0.43) HDAC6HDAC1HDAC2HDAC8HDAC3
SCHEMBL17520525 0.74 HDAC6 (0.69) HDAC6HDAC1HDAC2HDAC8SIRT2
SCHEMBL20605316 0.73 HDAC6 (0.73) HDAC6HDAC1HDAC2HDAC8HDAC3
SCHEMBL20629250 0.71 HDAC6 (0.57) HDAC6HDAC1HDAC2HDAC8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses UNIVERSITÄT REGENSBURG (DE) 2021-12-14 — — US disclosed
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses UNIVERSITÄT REGENSBURG (DE) 2021-12-14 — — US disclosed
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2020-10-01 — — US disclosed
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2020-10-01 — — US disclosed
WO-2019007836-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2019-01-10 — — WO disclosed
EP-3424925-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES Universität Regensburg (DE) 2019-01-09 — — EP disclosed
EP-3424925-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES Universität Regensburg (DE) 2019-01-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC1 2/4885HDAC2 4/4885
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC1 2/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback